Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative prostate cancer (DNPC) metastasizes by evading the immune system. The investigators also reported on the pre-clinical development of a new therapy, which, when given in combination with existing immunotherapies, appears to stop and even reverse metastasis in mouse models.
DNPC is difficult...
A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing...
The tobacco industry’s court-ordered anti-smoking advertisements reached just 40.6% of U.S. adults and 50.5% of current smokers in 2018, according...
The University of Texas MD Anderson Cancer Center, the official cancer center of the PGA TOUR, today announced its partnership with Joel Dahmen, PGA TOUR golf professional. Dahmen will serve as MD Anderson’s official PGA TOUR ambassador to educate the public on cancer prevention and to promote the institution’s mission to end cancer.
Dahmen is no stranger to the impact cancer can have on a family...
Abstract: LBA-006
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS)...
More than 140,000 people from around the world turned to our experts last year for their cancer care. Their trust in MD Anderson pushes us...
The University of Texas MD Anderson Cancer Center today named Darrow Zeidenstein, Ph.D., as chief development officer. With more than 25 years...
The University of Texas MD Anderson Cancer Center has cooperated fully in two surveys conducted by the Centers for Medicare and Medicaid Services...
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages...
ABSTRACT #7508
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination...